2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy

Fausto Roila, David Warr, Paul J. Hesketh, Richard J. Gralla, Jorn Herrstedt, Karin Jordan, Matti Aapro, Enzo Ballatori, Bernardo Rapoport

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: An update of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy published after the last MASCC/ESMO antiemetic consensus conference in 2009 has been carried out. Methods: A systematic literature search using PubMed from January 1, 2009 to January 6, 2015 with a restriction to papers in English was conducted. Results: Overall, two randomized phase II and seven randomized phase III studies plus the results of three subgroup analysis of large phase III trials and those of a pilot study have been included. Conclusions: In carboplatin-treated patients, a moderate benefit from adding an NK1 receptor antagonist to dexamethasone and a 5-HT3 receptor antagonist has been shown. However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained. At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. No routine prophylaxis for delayed emesis is recommended but in patients receiving moderately emetogenic chemotherapy with known potential for delayed emesis (e.g., oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2–3 can be considered.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - Aug 11 2016

Fingerprint

oxaliplatin
Nausea
Vomiting
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Drug Therapy
Dexamethasone
Antiemetics
Carboplatin
PubMed
Doxorubicin
Cyclophosphamide

Keywords

  • 5-HT3 receptor antagonists
  • Carboplatin
  • Irinotecan
  • Moderately emetogenic chemotherapy
  • NK1 receptor antagonists
  • Oxaliplatin

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology

Cite this

2016 updated MASCC/ESMO consensus recommendations : Prevention of nausea and vomiting following moderately emetogenic chemotherapy. / Roila, Fausto; Warr, David; Hesketh, Paul J.; Gralla, Richard J.; Herrstedt, Jorn; Jordan, Karin; Aapro, Matti; Ballatori, Enzo; Rapoport, Bernardo.

In: Supportive Care in Cancer, 11.08.2016, p. 1-6.

Research output: Contribution to journalArticle

Roila, Fausto ; Warr, David ; Hesketh, Paul J. ; Gralla, Richard J. ; Herrstedt, Jorn ; Jordan, Karin ; Aapro, Matti ; Ballatori, Enzo ; Rapoport, Bernardo. / 2016 updated MASCC/ESMO consensus recommendations : Prevention of nausea and vomiting following moderately emetogenic chemotherapy. In: Supportive Care in Cancer. 2016 ; pp. 1-6.
@article{f7b905fc22f94df3870886ecda77c18d,
title = "2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy",
abstract = "Purpose: An update of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy published after the last MASCC/ESMO antiemetic consensus conference in 2009 has been carried out. Methods: A systematic literature search using PubMed from January 1, 2009 to January 6, 2015 with a restriction to papers in English was conducted. Results: Overall, two randomized phase II and seven randomized phase III studies plus the results of three subgroup analysis of large phase III trials and those of a pilot study have been included. Conclusions: In carboplatin-treated patients, a moderate benefit from adding an NK1 receptor antagonist to dexamethasone and a 5-HT3 receptor antagonist has been shown. However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained. At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. No routine prophylaxis for delayed emesis is recommended but in patients receiving moderately emetogenic chemotherapy with known potential for delayed emesis (e.g., oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2–3 can be considered.",
keywords = "5-HT3 receptor antagonists, Carboplatin, Irinotecan, Moderately emetogenic chemotherapy, NK1 receptor antagonists, Oxaliplatin",
author = "Fausto Roila and David Warr and Hesketh, {Paul J.} and Gralla, {Richard J.} and Jorn Herrstedt and Karin Jordan and Matti Aapro and Enzo Ballatori and Bernardo Rapoport",
year = "2016",
month = "8",
day = "11",
doi = "10.1007/s00520-016-3365-1",
language = "English (US)",
pages = "1--6",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - 2016 updated MASCC/ESMO consensus recommendations

T2 - Prevention of nausea and vomiting following moderately emetogenic chemotherapy

AU - Roila, Fausto

AU - Warr, David

AU - Hesketh, Paul J.

AU - Gralla, Richard J.

AU - Herrstedt, Jorn

AU - Jordan, Karin

AU - Aapro, Matti

AU - Ballatori, Enzo

AU - Rapoport, Bernardo

PY - 2016/8/11

Y1 - 2016/8/11

N2 - Purpose: An update of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy published after the last MASCC/ESMO antiemetic consensus conference in 2009 has been carried out. Methods: A systematic literature search using PubMed from January 1, 2009 to January 6, 2015 with a restriction to papers in English was conducted. Results: Overall, two randomized phase II and seven randomized phase III studies plus the results of three subgroup analysis of large phase III trials and those of a pilot study have been included. Conclusions: In carboplatin-treated patients, a moderate benefit from adding an NK1 receptor antagonist to dexamethasone and a 5-HT3 receptor antagonist has been shown. However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained. At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. No routine prophylaxis for delayed emesis is recommended but in patients receiving moderately emetogenic chemotherapy with known potential for delayed emesis (e.g., oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2–3 can be considered.

AB - Purpose: An update of the recommendations for the prophylaxis of acute and delayed emesis induced by moderately emetogenic chemotherapy published after the last MASCC/ESMO antiemetic consensus conference in 2009 has been carried out. Methods: A systematic literature search using PubMed from January 1, 2009 to January 6, 2015 with a restriction to papers in English was conducted. Results: Overall, two randomized phase II and seven randomized phase III studies plus the results of three subgroup analysis of large phase III trials and those of a pilot study have been included. Conclusions: In carboplatin-treated patients, a moderate benefit from adding an NK1 receptor antagonist to dexamethasone and a 5-HT3 receptor antagonist has been shown. However, in oxaliplatin-treated patients, contrasting results about the role of NK1 receptor antagonists have been obtained. At present, it is not possible to suggest a specific 5-HT3 receptor antagonist to use for the prevention of acute emesis in these patients. No routine prophylaxis for delayed emesis is recommended but in patients receiving moderately emetogenic chemotherapy with known potential for delayed emesis (e.g., oxaliplatin, doxorubicin, cyclophosphamide) the use of dexamethasone for days 2–3 can be considered.

KW - 5-HT3 receptor antagonists

KW - Carboplatin

KW - Irinotecan

KW - Moderately emetogenic chemotherapy

KW - NK1 receptor antagonists

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=84981170540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981170540&partnerID=8YFLogxK

U2 - 10.1007/s00520-016-3365-1

DO - 10.1007/s00520-016-3365-1

M3 - Article

C2 - 27510316

AN - SCOPUS:84981170540

SP - 1

EP - 6

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -